 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| BPI-421286 / Betta Pharma, RMC-6291 / Revolution Medicines, HBI-2438 / HUYA Bioscience
Clinical, Monotherapy: A12-2. 🎯therapy: #KRASG12Ci-monotherapy #clinicaltrials These are recruiting Ph 1 trials looking at dose finding & safety signals ​​📌HBI-2438 https://t.co/KTGUQQBpuB n=44 📌RMC-6291 https://t.co/UzhjiYhw7Z n=117 📌BPI-421286 https://t.co/O5bAH1CqKw n=80 #CRCTrialsChat (Twitter) - Mar 23, 2023
- ||| BPI-421286 / Betta Pharma
New P1 trial, Metastases: A Phase 1?Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Apr 6, 2022
P1, N=80, Recruiting, Sponsor: Betta Pharmaceuticals Co., Ltd.
- BPI-421286 / Betta Pharma
BPI-421286: A highly potent small molecule inhibitor targeting KRASG12C mutation (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6904;
Taken together, BPI-421286 is a highly potent and selective KRASG12C inhibitor, with favorable ADME properties and wide therapeutic index in pre-clinical toxicology studies. BPI-421286 is currently in Phase 1 clinical study.